Amarin Co. plc (NASDAQ:AMRN) Director David M. Stack sold 51,991 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $22.28, for a total transaction of $1,158,359.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

NASDAQ AMRN opened at $21.87 on Tuesday. The company has a current ratio of 2.20, a quick ratio of 1.84 and a debt-to-equity ratio of 0.30. The business’s fifty day moving average price is $19.52. The company has a market cap of $7.16 billion, a P/E ratio of -56.08 and a beta of 1.18. Amarin Co. plc has a 1 year low of $2.35 and a 1 year high of $23.91.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.04. The business had revenue of $73.30 million during the quarter, compared to the consensus estimate of $67.30 million. Amarin had a negative net margin of 45.16% and a negative return on equity of 450.07%. Amarin’s quarterly revenue was up 67.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.07) EPS. As a group, sell-side analysts anticipate that Amarin Co. plc will post -0.24 earnings per share for the current fiscal year.

AMRN has been the topic of several analyst reports. Jefferies Financial Group restated a “buy” rating and set a $30.00 price target on shares of Amarin in a research note on Tuesday, July 9th. BidaskClub lowered shares of RigNet from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 21st. Stifel Nicolaus set a $27.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. HC Wainwright set a $51.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Wednesday, July 3rd. Finally, Cantor Fitzgerald set a $35.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Thursday, July 11th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $30.75.

A number of institutional investors have recently modified their holdings of the business. Global Retirement Partners LLC boosted its holdings in Amarin by 30.7% in the 1st quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 802 shares during the period. F3Logic LLC boosted its holdings in Amarin by 8.0% in the 1st quarter. F3Logic LLC now owns 12,515 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 925 shares during the period. UBP Investment Advisors SA boosted its holdings in Amarin by 7.7% in the 1st quarter. UBP Investment Advisors SA now owns 14,000 shares of the biopharmaceutical company’s stock valued at $291,000 after purchasing an additional 1,000 shares during the period. Executive Wealth Management LLC boosted its holdings in Amarin by 17.0% in the 1st quarter. Executive Wealth Management LLC now owns 8,600 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 1,250 shares during the period. Finally, Comerica Bank boosted its holdings in Amarin by 8.0% in the 1st quarter. Comerica Bank now owns 18,481 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 1,376 shares during the period. 47.62% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Featured Article: If I purchase shares through a brokerage account, am I the holder of record?

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.